# Development of a COVID-19 Vaccine

> **NIH NIH N01** · HDT BIO CORPORATION · 2022 · $2,717,614

## Abstract

To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation.

## Key facts

- **NIH application ID:** 10696929
- **Project number:** 75N93020C00052-P00002-9999-1
- **Recipient organization:** HDT BIO CORPORATION
- **Principal Investigator:** STEVEN REED
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,717,614
- **Award type:** —
- **Project period:** 2020-09-01 → 2023-10-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10696929

## Citation

> US National Institutes of Health, RePORTER application 10696929, Development of a COVID-19 Vaccine (75N93020C00052-P00002-9999-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10696929. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*